Sponsors (6)
The bill increases federal clarity and safety oversight for cannabinoid products (including a federal age limit and an HHS compounds list) but does so by expanding FDA/HHS authority and enforcement in ways that will raise compliance costs, legal risk, and potential market disruption for businesses and some consumers.
Consumers (including patients with chronic conditions) and retailers: Finished cannabinoid hemp products are brought under the FD&C Act, creating clearer safety, labeling, testing, and adulteration standards that should improve product consistency and reduce unsafe products.
Industry, regulators, and consumers: HHS must publish and update a list of cannabinoid compounds within one year, improving transparency about which compounds are treated as cannabinoids and helping producers and regulators plan compliance.
Hospitals, health systems, patients, and public-health officials: The bill preserves FDA/HHS regulatory and public-health emergency authorities, maintaining federal oversight of drug/medical-product safety and emergency response capabilities.
Small businesses, manufacturers, and retailers: The bill expands regulatory coverage and imposes new manufacturing, testing, labeling, registration, and age‑verification requirements, creating substantial compliance costs and administrative burdens (including immediate costs upon enactment).
Consumers (including patients who use delta‑8 or synthetic cannabinoids): Many currently sold cannabinoid products could become prohibited or pulled from shelves, reducing product availability and potentially raising prices.
Small businesses and state regulators: The bill gives HHS broad authority to deem compounds cannabinoids by regulation and to set standards, creating regulatory uncertainty until the agency issues rules and the compounds list.
Based on analysis of 5 sections of legislative text.
Creates federal definitions and regulations for cannabinoid hemp products, requires an HHS cannabinoid list, mandates manufacturing/testing rules, and expands FDA enforcement and penalties.
Introduced January 22, 2026 by H. Morgan Griffith · Last progress January 22, 2026
Creates a federal regulatory framework for products that contain cannabinoids derived from hemp or made to behave like hemp cannabinoids. It defines “cannabinoid” and “cannabinoid hemp product,” requires HHS to publish and update a list of covered cannabinoid compounds, and adds manufacturing, testing, labeling and sale restrictions plus new enforcement tools and criminal penalties for violations. Applies these rules to cannabinoid hemp products introduced into interstate commerce on or after enactment, expands FDA enforcement powers (including detention, seizure, and enhanced criminal penalties), and preserves existing FDA and Public Health Service authorities unless expressly changed by the Act.